AR035072A1 - Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, procesos para la preparacion de tales composiciones y procesos para la preparacion de dichos compuestos - Google Patents

Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, procesos para la preparacion de tales composiciones y procesos para la preparacion de dichos compuestos

Info

Publication number
AR035072A1
AR035072A1 ARP010105405A ARP010105405A AR035072A1 AR 035072 A1 AR035072 A1 AR 035072A1 AR P010105405 A ARP010105405 A AR P010105405A AR P010105405 A ARP010105405 A AR P010105405A AR 035072 A1 AR035072 A1 AR 035072A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
alkyloxy
halo
hydrogen
Prior art date
Application number
ARP010105405A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR035072A1 publication Critical patent/AR035072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Bifenilcarboxamidas de fórmula (1), los N-óxidos, las sales de adición de ácido farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de los mismos, en donde: p1, p2 y p3 son números enteros cada uno en forma independiente de 1 a 3; cada R1 se selecciona independientemente entre hidrógeno, alquilo C1-4, alquiloxi C1-4, halo, hidroxi, mercapto, ciano, nitro, alquiltio C1-4 o polihaloalquilo C1-4, amino, alquilamino C1-4 y di(alquil C1-4)amino; cada R2 se selecciona independientemente entre hidrógeno, alquilo C1-4, alquiloxi C1-4, halo o trifluorometilo; R3 es hidrógeno o alquilo C1-4; cada R4 se selecciona independientemente entre alquilo C1-4, alquiloxi C1-4, halo o trifluorometilo; Z es un radical bivalente de fórmula (a-1), (a-2), (a-3) ó (a-4), en donde n es un número entero de 2 a 4 y la porción -(CH2)n- en el radical (a-1) puede ser sustituida opcionalmente con 1 ó 2 alquilo C1-4; m y m' son números enteros de 1 a 3; R5 y R6 son independientemente seleccionados, en forma individual, entre hidrógeno, alquilo C1-6 o arilo; X1 y X2 son independientemente seleccionados, en forma individual, entre CH, N o un átomo de carbono hibridado con sp2 y en el radical (a-1) por lo menos uno de X1 ó X2 es N; A representa un enlace, alcanodiilo C1-6 optativamente sustituido con 1 ó 2 grupos seleccionados entre arilo, heteroarilo y cicloalquilo C3-10; B representa hidrógeno, alquilo C1-10; arilo o heteroarilo cada uno optativamente sustituido con un grupo seleccionado entre halo, ciano, nitro, alquiloxi C1-4, amino, alquilamino C1-10, di(alquil C1-10)amino, acilo C1-10, alquiltio C1-10, alcoxicarbonilo C1-10, alquilaminocarbonilo C1-10 y di(alquil C1-10)aminocarbonilo; arilalquilo C1-10, heteroarilalquilo C1-10, cicloalquilo C3-10, polihaloalquilo C1-6, alquenilo C3-6, alquinilo C3-6, NR7R8, u OR9; en donde R7 y R8 cada uno representa en forma independiente hidrógeno, alquilo C1-10, arilo o heteroarilo cada uno optativamente sustituido con un grupo seleccionado entre halo, ciano, alquiloxi C1-4, amino, alquilamino C1-10, di(alquil C1-10)amino, acilo C1-10, alquiltio C1-10, alquilaminocarbonilo C1-10 y di(alquil C1-10)aminocarbonilo; arilalquilo C1-10, heteroarilalquilo C1-10, cicloalquilo C3-10, policicloalquilo C7-10, polihaloalquilo C1-6, alquenilo C3-8, alquinilo C3-8, benzo-cicloalquilo C5-8 fusionado y en donde R7 y R8 tomados en conjunto con el átomo de nitrógeno al cual están unidos pueden formar un radical heterocíclico saturado C4-8; y en donde R9 representa alquilo C1-10, arilo o heteroarilo cada uno sustituido en forma optativa con un grupo seleccionado entre halo, ciano, nitro, alquiloxi C1-4, amino, alquilamino C1-10, di(alquil C1-10)amino, acilo C1-10, alquiltio C1-10, alquilaminocarbonilo C1-10 y di(alquil C1-10)aminocarbonilo; arilalquilo C1-10, heteroarilalquilo C1-10, cicloalquilo C3-10, policicloalquilo C7-10, polihaloalquilo C1-6, alquenilo C3-8, alquinilo C3-8, o benzo-cicloalquilo C5-8 fusionado. Dichos compuestos tienen actividad inhibidora de la apolipoproteína B y actividad reductora de lípidos concomitante, y son útiles en el tratamiento de la hiperlipidemia, obesidad y diabetes tipo II. También se dan a conocer: composiciones farmacéuticas que las comprenden, procesos para la preparación de tales composiciones y procesos para la preparación de dichos compuestos.
ARP010105405A 2000-11-21 2001-11-20 Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, procesos para la preparacion de tales composiciones y procesos para la preparacion de dichos compuestos AR035072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00204150 2000-11-21

Publications (1)

Publication Number Publication Date
AR035072A1 true AR035072A1 (es) 2004-04-14

Family

ID=8172315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105405A AR035072A1 (es) 2000-11-21 2001-11-20 Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, procesos para la preparacion de tales composiciones y procesos para la preparacion de dichos compuestos

Country Status (32)

Country Link
US (5) US7135586B2 (es)
EP (1) EP1339685B1 (es)
JP (1) JP4190283B2 (es)
KR (1) KR20030051718A (es)
CN (1) CN1289481C (es)
AR (1) AR035072A1 (es)
AT (1) ATE344243T1 (es)
AU (2) AU2002219115B2 (es)
BG (1) BG107805A (es)
CA (1) CA2427660C (es)
CZ (1) CZ20031638A3 (es)
DE (1) DE60124296T2 (es)
DK (1) DK1339685T3 (es)
EA (1) EA006101B1 (es)
EE (1) EE200300234A (es)
ES (1) ES2275759T3 (es)
GC (1) GC0000312A (es)
HK (1) HK1073310A1 (es)
HU (1) HUP0400926A3 (es)
IL (2) IL155945A0 (es)
JO (1) JO2409B1 (es)
MX (1) MXPA03004465A (es)
MY (1) MY134167A (es)
NO (1) NO20032272D0 (es)
NZ (1) NZ526495A (es)
PA (1) PA8532001A1 (es)
PL (1) PL205290B1 (es)
PT (1) PT1339685E (es)
SI (1) SI1339685T1 (es)
SK (1) SK7522003A3 (es)
WO (1) WO2002042271A2 (es)
ZA (1) ZA200303910B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
WO2002098839A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
SG165154A1 (en) 2002-02-28 2010-10-28 Japan Tobacco Inc Ester compound and medical use thereof
NZ534831A (en) 2002-03-13 2007-01-26 Janssen Pharmaceutica Nv Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
AU2003212335B8 (en) 2002-03-13 2009-04-23 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
JP2006516028A (ja) * 2002-12-20 2006-06-15 ファイザー・プロダクツ・インク ミクロソームトリグリセリド輸送タンパク質阻害剤
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
FR2871463B1 (fr) * 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8338426B2 (en) 2007-07-03 2012-12-25 Janssen Pharmaceutica Nv Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor
US10491357B2 (en) * 2010-07-12 2019-11-26 Entropic Communications Llc Method and apparatus for using dynamic subchannels in a communications network

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910930A (en) * 1973-01-04 1975-10-07 Janssen Pharmaceutica Nv 1-{55 1-{8 2-(1,4-Benzodioxan-2-yl)-2-hydroxyethyl{9 -4-piperidyl{56 -2-benzimidazolinones
US3929801A (en) * 1973-11-20 1975-12-30 Janssen Pharmaceutica Nv 2-Benzimidazolinones
US3929601A (en) * 1974-03-26 1975-12-30 Us Energy Synthesis of pentafluorides
DE2852203C3 (de) * 1978-12-02 1982-03-11 Ibm Deutschland Gmbh, 7000 Stuttgart Lichtleiteinrichtung für eine mit Auflicht betriebene Abbildungsvorrichtung
US4231576A (en) * 1979-02-21 1980-11-04 Perkins Sonnie J Golf club head alignment apparatus
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444764A (en) * 1979-08-06 1984-04-24 The Dow Chemical Company Phosphorus esters of alkylcycloalkyl-5-pyrimidinols and control of corn rootworm and western spotted cucumber beetle with them
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
DE3124366A1 (de) * 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
DE3410498A1 (de) * 1984-03-22 1985-10-03 Hoechst Ag, 6230 Frankfurt N-bicycloheptyl- und n-bicycloheptenyl-imidazole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) * 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
GB8716059D0 (en) * 1987-07-08 1987-08-12 Anderson Strathclyde Plc Mining machine
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5064856A (en) * 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DE4040203A1 (de) 1990-12-15 1992-06-17 Roehm Gmbh Eingetruebte kunststoffelemente
WO1992018113A1 (en) * 1991-04-18 1992-10-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of a new ehrlichia species from a patient suffering from ehrlichiosis
DE4140540A1 (de) * 1991-12-09 1993-06-17 Bayer Ag Neue azaheterocyclylmethyl-chromane
EP0618803A4 (en) * 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
EP0567026B1 (en) 1992-04-20 2003-03-26 Takeda Chemical Industries, Ltd. 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
US5279454A (en) 1992-04-24 1994-01-18 Eastman Kodak Company Straight through lateral constraint
US5327875A (en) * 1993-02-19 1994-07-12 Hall S Franklin Vapor enhanced carburetion system
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
US5780248A (en) * 1993-07-15 1998-07-14 Ortho Diagnostic Systems, Inc. Foil sealed cassette for agglutination reactions and liner therefor
FI93396C (fi) 1993-08-17 1995-03-27 Petetronic Tmi P Kinnunen Optinen menetelmä nesteen pinnankorkeuden mittaamiseksi
SK282402B6 (sk) 1993-08-19 2002-01-07 Janssen Pharmaceutica N. V. Deriváty dihydrobenzopyránu, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutický prostriedok na ich báze
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995015693A1 (de) * 1993-12-07 1995-06-15 S & R Maschinenbau Gesellschaft mit beschränkter Haftung Verfahren und vorrichtung zum backen von kuchen
JPH086412A (ja) * 1994-06-20 1996-01-12 Canon Inc 加熱装置および画像形成装置
CA2200981A1 (en) 1994-10-04 1996-04-11 Hisashi Takasugi Urea derivatives and their use as acat-inhibitors
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5536859A (en) 1995-02-27 1996-07-16 Amoco Corporation Alpha-olefin catalyst and process
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
US5919795A (en) * 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
US5696196A (en) * 1995-09-15 1997-12-09 Egyptian Lacquer Mfg. Co. EMI/RFI-shielding coating
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6542607B1 (en) 1996-09-03 2003-04-01 Siemens Aktiengesellschaft Device and method for the cryptographic processing of a digital data stream presenting any number of data
FR2756027B1 (fr) 1996-11-15 1999-01-15 Dimos Crochet de securite
AU716151B2 (en) * 1996-11-27 2000-02-17 Pfizer Inc. Apo B-secretion/MTP inhibitory amides
DE19649751C2 (de) 1996-11-30 1999-12-30 Cts Fahrzeug Dachsysteme Gmbh Dachaufbau für Fahrzeuge, insbesondere Personenkraftwagen
US5876070A (en) 1996-12-11 1999-03-02 Kennecott Holdings Corporation Pipe flange connection for pressure retaining, abrasive/corrosive service
GB9626045D0 (en) 1996-12-14 1997-01-29 Rover Group A vehicle roll stabilising system
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US5966677A (en) 1997-02-28 1999-10-12 Fiekowsky; Peter J. High accuracy particle dimension measurement system
GB9705206D0 (en) 1997-03-13 1997-04-30 Automotive Prod Italia Drum brakes
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
US5988950A (en) * 1997-11-18 1999-11-23 Atlantic Richfield Company Method and system for preventing upward migration of contaminants in soil
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US5989950A (en) * 1998-01-26 1999-11-23 Texas Instruments - Acer Incorporated Reduced mask CMOS salicided process
US6173351B1 (en) 1998-06-15 2001-01-09 Sun Microsystems, Inc. Multi-processor system bridge
US6133217A (en) 1998-08-28 2000-10-17 Huntsman Petrochemical Corporation Solubilization of low 2-phenyl alkylbenzene sulfonates
US5985577A (en) * 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
AU1959100A (en) 1998-12-03 2000-06-19 Alvaro Lucio Process for thermal treatment of inorganic and organic materials in a series of small shafts, and the apparatus to perform ditto process
DE60014896T2 (de) 1999-06-02 2006-02-02 Janssen Pharmaceutica N.V. Pyrrolidinyl, piperidinyl oder homopiperidinyl substituierte (benzodioxan, benzofuran oder benzopyran) derivate
HUP0201404A3 (en) 1999-06-02 2005-02-28 Janssen Pharmaceutica Nv Aminoalkyl substituted benzodioxan, benzofuran or benzopyran derivatives, pharmaceutical compositions containing them and their use and process for their preparations
WO2001077077A1 (en) 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2352B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Compounds for the treatment of non-adaptation of the bottom of the uterus
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
US7101891B2 (en) 2001-04-09 2006-09-05 Eli Lilly And Company Compounds and pharmaceutical compositions for inhibiting MRP1
GB0423422D0 (en) * 2004-10-21 2004-11-24 Bard Inc C R Medical device for fluid flow, and method of forming such device

Also Published As

Publication number Publication date
PT1339685E (pt) 2007-02-28
US20040102490A1 (en) 2004-05-27
US7135586B2 (en) 2006-11-14
WO2002042271A3 (en) 2002-11-21
DE60124296T2 (de) 2007-05-31
JP4190283B2 (ja) 2008-12-03
DE60124296D1 (de) 2006-12-14
US20080009522A1 (en) 2008-01-10
AU1911502A (en) 2002-06-03
PL205290B1 (pl) 2010-03-31
IL155945A (en) 2009-06-15
CA2427660C (en) 2010-01-19
MXPA03004465A (es) 2003-08-19
HUP0400926A2 (hu) 2004-07-28
SK7522003A3 (en) 2004-04-06
MY134167A (en) 2007-11-30
DK1339685T3 (da) 2007-03-12
SI1339685T1 (sl) 2007-04-30
US7244848B2 (en) 2007-07-17
GC0000312A (en) 2006-11-01
NZ526495A (en) 2004-06-25
KR20030051718A (ko) 2003-06-25
CZ20031638A3 (cs) 2004-02-18
US20060128972A1 (en) 2006-06-15
ZA200303910B (en) 2004-09-01
US20060128973A1 (en) 2006-06-15
PA8532001A1 (es) 2002-10-28
EP1339685B1 (en) 2006-11-02
EA006101B1 (ru) 2005-08-25
WO2002042271A2 (en) 2002-05-30
NO20032272L (no) 2003-05-20
CN1289481C (zh) 2006-12-13
US7304167B2 (en) 2007-12-04
CA2427660A1 (en) 2002-05-30
PL361633A1 (en) 2004-10-04
CN1568312A (zh) 2005-01-19
JP2004521870A (ja) 2004-07-22
NO20032272D0 (no) 2003-05-20
EA200300597A1 (ru) 2003-10-30
BG107805A (bg) 2004-01-30
HK1073310A1 (en) 2005-09-30
EE200300234A (et) 2003-08-15
US7405307B2 (en) 2008-07-29
ES2275759T3 (es) 2007-06-16
HUP0400926A3 (en) 2008-03-28
US7538124B2 (en) 2009-05-26
ATE344243T1 (de) 2006-11-15
AU2002219115B2 (en) 2007-01-04
EP1339685A2 (en) 2003-09-03
US20080275087A1 (en) 2008-11-06
JO2409B1 (en) 2007-06-17
IL155945A0 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
AR035072A1 (es) Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, procesos para la preparacion de tales composiciones y procesos para la preparacion de dichos compuestos
AR035056A1 (es) Compuestos de poliarilcarboxamida, procesos para su preparacion , intermediarios utiles para la preparacion de tales compuestos, composiciones farmaceuticas que comprenden tales compuestos, y, el uso de tales compuestos en la fabricacion de medicamentos
UY28144A1 (es) Agentes terapéuticos
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR034244A1 (es) Derivados de 4-aminopiperidina y su uso como medicamento
UY28374A1 (es) Agentes terapéuticos
AR048528A1 (es) Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
AR054881A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, un proceso para su preparacion, una composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento para el tratamiento de la hepatitis c
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
AR046600A1 (es) Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
UY28752A1 (es) Agentes terapeuticos
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
AR035814A1 (es) Bifenilcarboxamidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, y procesos para preparar dichos compuestos.
AR040412A1 (es) Derivados de sulfamato sustituido como anticonvulsivo
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20020084A1 (es) N-(glicilo sustituido)-2-ciano-pirrolidinas como inhibidores de la dipeptidilpeptidasa-iv
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BR112022007488A2 (pt) Forma cristalina de base livre de um receptor c5a de componente do complemento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal